- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01632917
Open-Label Pharmacokinetic Study of Final Formulations of ATX-101
September 24, 2012 updated by: Kythera Biopharmaceuticals
Phase 1, Open-Label, Randomized, Safety and Pharmacokinetic Study of Two Final Formulations of ATX-101 (Sodium Deoxycholate Injection) Following Subcutaneous Injections in the Submental Fat
The objectives of this trial are to evaluate the safety and tolerability of ATX-101 injections and to characterize the pharmacokinetic profile of the two ATX-101 formulations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objectives of this trial are to evaluate the safety and tolerability of ATX-101 injections and to characterize the pharmacokinetic profile of the two ATX-101 formulations that are expected to be the final formulations.
ATX-101 will be administered into the submental fat as subcutaneous injections using the maximum proposed dosing regimen that is intended for labeling.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miramar, Florida, United States, 33027
- Comprehensive Clinical Development
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Presence of sufficient submental fat into which 50 subcutaneous injections of ATX-101 spaced on a 1.0-cm grid can be safely administered based on the investigator's judgment.
- Males or nonpregnant, nonlactating females who are aged 18 to 65 years, inclusive, on the date of dosing with ATX-101. Females must have a negative serum human chorionic gonadotropin (hCG) test result from a sample obtained during the screening period and after admission to the research facility, but before the dose of study material. Females of postmenopausal status must not have had menses for at least one year and if younger than 55 years of age must have a serum FSH level ≥ 35 mIU/mL. Females of childbearing potential must agree to practice adequate contraception, in the judgment of the investigator, during the course of the trial.
- Serum hemoglobin test result of 11.0 g/dL or greater and negative hepatitis B, hepatitis C, and HIV test result within 28 days before the dose of study material.
- Willing and able to comply with and understand the visit schedule and all of the protocol-specified tests and procedures.
- Medically able to undergo the administration of study material as determined by clinical and laboratory evaluations obtained within 28 days before dosing with study material for which the investigator identifies no clinically significant abnormality.
- Signed informed consent obtained before any study-specific procedure is conducted.
Exclusion Criteria:
- History of any intervention to treat submental fat (e.g. liposuction, surgery, or lipolytic agents).
- History of trauma associated with the chin or neck areas, which in the judgment of the investigator may affect evaluation of safety of treatment.
- Loose skin in the neck or chin area for which reduction in submental fat may, in the judgment of the investigator, result in a cosmetically unacceptable outcome.
- Prominent platysmal bands at rest that interfere with the evaluation of submental fat.
- Evidence of any cause of enlargement in the submental area other than localized subcutaneous fat.
- Body mass index (BMI) > 40.0 at the screening visit. Refer to Appendix B.
- Use of tobacco or nicotine-containing products within 3 months prior to dose.
- Any blood donation or significant blood loss within 56 days before the dose of study material or plasma donation within 7 days before the dose of study material.
- A result on coagulation tests (PT, PTT) obtained within 28 days before the dose of study material that indicates the presence of any clinically significant bleeding disorder.
- Any medical condition that would interfere with the assessment of safety in this trial or would compromise the ability of the subject to undergo study procedures or to give informed consent.
- Treatment with fish oil, aspirin, or nonsteroidal anti-inflammatory agents (NSAIDS), except acetaminophen, within 7 days before dosing, or any anticipated need for agents with anticoagulative effects (e.g. warfarin, heparin) during the course of the trial.
- Treatment with oral anticoagulants (e.g. warfarin) within 30 days before dosing with study material.
- Treatment with radio frequency, laser procedures, chemical peels, or dermal fillers in the neck or chin area within 12 months before dosing with the study material, or botulinum toxin injections in the neck or chin area within 6 months before dosing with the study material.
- History of sensitivity to any components of the study material.
- History of drug or alcohol abuse, in the judgment of the investigator, within two years before dosing with the study material.
- Presence of a positive urine drug or alcohol screening test result obtained from a sample obtained during the screening period and/or after admission to the research facility for the confinement period, but before dosing with the study material.
- Previous enrollment into a trial of ATX-101.
- Treatment with an investigational device or agent within 30 days before dosing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ATX-101 - EU
Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
|
EU ATX-101, 10 mg/mL, one dosing session in the submental area
|
Experimental: ATX-101 - US
Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
|
US ATX-101, 10 mg/mL, one dosing session in the submental area
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of ATX-101 injections as assessed by incidence, severity and duration of AEs of ATX-101 administered into subcutaneous fat in the submental and abdomen area
Time Frame: 8 days
|
Spontaneously reported adverse events, laboratory test results, and treatment area evaluations including, but not limited to evaluation of edema, bruising, dysphagia, dysphonia, erythema, dyspigmentation, induration, numbness, pain, paresthesia, and pruritus.
|
8 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To compare the pharmacokinetic profile (Cmax, tmax, AUC, half-life) of ATX-101 administered into subcutaneous fat in the submental area
Time Frame: 8 days
|
Blood sampling at specified time points before and after dosing with ATX-101 for analysis of deoxycholate concentrations in the plasma.
|
8 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Patricia Walker, MD, PhD, Kythera Biopharmaceuticals, Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Actual)
July 1, 2012
Study Completion (Actual)
July 1, 2012
Study Registration Dates
First Submitted
June 29, 2012
First Submitted That Met QC Criteria
June 29, 2012
First Posted (Estimate)
July 3, 2012
Study Record Updates
Last Update Posted (Estimate)
September 25, 2012
Last Update Submitted That Met QC Criteria
September 24, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ATX-101-12-32
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on ATX-101 - EU
-
Benjamin IzarTerminatedLeiomyosarcoma | LiposarcomaUnited States
-
Kythera BiopharmaceuticalsCompleted
-
Kythera BiopharmaceuticalsCompletedHealthy | Submental FatUnited States, Canada, Australia, United Kingdom
-
Kythera BiopharmaceuticalsCompleted
-
Kythera BiopharmaceuticalsCompleted
-
Kythera BiopharmaceuticalsCompleted
-
Kythera BiopharmaceuticalsCompleted
-
Kythera BiopharmaceuticalsCompletedHealthy | Submental FatUnited States, Canada
-
Kythera BiopharmaceuticalsBayerCompletedModerate or Severe Submental FullnessGermany, France, Belgium, Spain, United Kingdom
-
Kythera BiopharmaceuticalsCompletedPhase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)Moderate or Severe Submental FullnessUnited Kingdom, Canada, Australia